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ABSTRACT 
Cytokines play an essential role in normal cell growth and the regulation of immune function. The emergence of Janus Kinase Enzyme inhibitors 
promises the start of a revolution in the treatment of several chronic diseases. Their efficacy and safety profile have been demonstrated in multiple 
trials and they have been licensed for the treatment of a number of diseases including RA and PsA. Moreover, the use of highly selective Janus Kinase 
Enzyme inhibitors is currently being studied aiming to reduce side effects compared with traditional JAKinibs, an example of that would be the 
recent FDA approved upadacitinib. The Janus Kinase Enzyme inhibitorsmay supplant the classical biologic agents in the treatment of autoimmune 
diseases, since they exhibitthe advantages of oral administration, simultaneous blockade of multiple cytokines, reversibility and the lack of 
immunogenicity. 
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Cytokines play an essential role in normal cell growth and the 
regulation of immune function. Moreover, the role of cytokines in 
the pathophysiology of various autoimmune diseases and 
malignancies has become well established in recent years. As a 
result, the targeting of cytokines has become an attractive 
mechanism for developing drugs that may alter the course of such 
diseases.1
Cytokines were first targeted with the emergence of monoclonal 
antibodies. Monoclonal antibodies also known as ‘biologic’ agents, 
target the cytokines outside of the cell by blocking the cytokine 
itself, or its receptor.
Janus Kinase Enzyme inhibitors (JAKinibs) are a novel 
class of drugs used mainly in the treatment of autoimmune diseases 
and haematologic malignancies. 
JAK is a type of tyrosine kinase enzyme, it is part of a cytokine 
signaling pathway known as the Janus kinase/signal transducer and 
activator of transcription (JAK/STAT) signaling pathway, used 
mainly by types I/II cytokine signaling receptors [1, 2]. 
3
The first JAKinibs licensed for use in clinical practice was 
Ruxolitinib
 On the other hand, JAKinibs work inside the 
cell to block the intracellular signaling pathway, and thus are able to 
block the activity of multiple pro-inflammatory cytokines 
simultaneously [1, 2, 4]. 
2. It has been used in the treatment of haematologic 
malignancies such asmyelofibrosis and polycythemiavera. 
Tofacitinib and baricitinib are also approved by the United 
States of America Food and Drug Administration (FDA) for the 
treatment of Rheumatoid Arthritis (RA), whiletofacitinib is 
approved for the treatment of psoriatic arthritis (PsA) and 
ulcerative colitis (UC).1Other JAKinibis (table 1) are currently 
undergoing different phases of clinical trials1
 
, including a 
promising JAK 1 selective inhibitor Upadacitinib, which has been 
recently FDA approved for the treatment of rheumatoid arthritis 
(RA) [5, 6]. 
Table 1: Showing some of the current JAKinibis [1, 2, 7-9] 




Example of cytokines inhibited Use 
Ruxolitinib (Jakavi) JAK1, JAK2 IL-6, EPO, IFN Myelofibrosis, polycythemia vera 
Tofacitinib (Xeljanz) JAK1, JAK3 Common gamma chain cytokines (IL-
2,4,7,8,15,21), IFN-γ, IL-6 
Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis 
Baricitinib (Olumiant) JAK1, JAK2 Gamma chain cytokines, IL-6, GM-CSF, IFN-γ Rheumatoid arthritis 
Upadacitinib (Rinvoq) JAK 1 IL-6, IFN-γ Rheumatoid arthritis (approved), psoriatic arthritis, 
ulcerative colitis, Crohn’s disease, atopic dermatitis, giant 
cell arteritis 
 
Mechanism of action 
Over 50 different cytokines including interferons, interleukins, colony 
stimulating factors and hormones bind to type I and type II cytokine 
receptors. This superfamily of receptors utilizes the action of the JAK 
in order to transduce the signal into the nucleus with the help of the 
STAT protein. There are four known types of the intracellular enzyme 
JAK (JAK 1, 2, 3, TYK2) [10]. When a specific cytokine binds to its 
corresponding type I/II receptor, the receptor first undergoes a 
conformational change, this recruits the JAK enzymes and then 
phosphorylates them. This is a key event in signal transduction, as the 
phosphorylation of the JAKs triggers their enzymatic activity. The 
phosphorylated JAK transfers a phosphate group from ATP to specific 
residues on cytokine receptors (fig. 1) [11]. 
The next step depends on the STAT protein, which comprises the 
second part of the JAK-STAT pathway. The phosphorylated residues 
on the receptors act as docking sites for the STAT proteins. The 
phosphorylated STAT proteins dimerize and head towards the 
nucleus to trigger or modify gene transcription [12]. JAKinibs, 
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reversibly bind to the ATP binding pockets of the JAKs and thus 
inhibit phosphorylation of the tyrosine residues, thereby inhibiting 
their enzymatic activity, and as a result inhibit the whole process of 
downstream signaling (fig. 1) [1]. 
 
 
Fig. 1: Key steps of the JAK-STAT pathway 
 
Trials 
Several clinical trials have been conducted using JAKinibis and many 
more are ongoing of note arethree recently published trials, 
summarised below:  
1. RA-BEAM is a phase 3, double blind, placebo and active 
controlled trial by Eli Lilly™ and Incyte™involved participants with 
active RA receiving background methotrexate (MTX). The 
participants were randomly assigned to a placebo group, baricitinib 
or adalimumab. All patients received background MTX [13, 14]. The 
study concluded that “in patients with rheumatoid arthritis who had 
experienced an inadequate response to methotrexate, baricitinib 
was associated with significant clinical improvements as compared 
with placebo and adalimumab ”[14]. 
2. OPAL BROADEN a phase 3, double-blind, active controlled, 
placebo-controlled trial by Pfizer™ involved participants with active 
psoriatic arthritis who had inadequate response to conventional 
synthetic disease-modifying antirheumatic drugs (csDMARDs) [15, 
16]. The participants were assigned to tofacitinib, adalimumab or a 
placebo group. The study concluded that “the efficacy of tofacitinib 
was superior to that of placebo at month 3 in patients with psoriatic 
arthritis who had previously had an inadequate response to 
conventional synthetic DMARDs”[16]. 
3. SELECT COMPARE by Abbvie™is a phase 3, randomized, double-
blind study, comparing upadacitinib to placebo and adalimumab, in 
patients with active RA with inadequate response to MTX. The study 
concluded that upadacitinib was superior to placebo and 
adalimumab in terms of improvement of RA signs, symptoms and 
physical function in the MTX inadequateresponders’ population. 
Moreover, radiographic progression was markedly lower with 
upadacitinib compared to placebo. The safety profile of upadacitinib 
was similar to that of adalimumab, except for an increased risk of 
herpes zoster infection and elevated Creatine Phosphokinase (CPK) 
levels in upadacitinib [5, 17]. 
Advantages of JA kinibs 
The main advantage of JAKinibs over biologic disease modifying anti 
rheumatic drugs (bDMARDs) is the fact that JAKinibs can be 
administered orally, as they are made up of small molecules, whereas 
biologic agents, are made of larger molecules and are administered as 
injections or as infusions. However, one could argue that in some 
patients, parenteral administration of a drug may ensure maximum 
compliance [18]. In addition to that, JAKinibs when compared to 
bDMARDshave the advantage of targeting multiple cytokines at once9
As cytokines are essential for normal immune function, cellular 
growth, and bone marrow function, inhibiting their functions may 
produces predictable side effects related to the physiological 
processes. These include but are not limited to: increased risk of 
development of infections, anemia, leukopenia, hyperlipidemia, 
increased cardiovascular disease risk, gastrointestinal perforation 
and malignancies (table 2) [10]. 
, 
and reversibility of binding to their targetsuch that, theoretically 
speaking, their effects can be rapidly reversed for example in the event 
of infections or pre-operatively [8, 18]. 
Furthermore, biologic agents with repetitive administration 
maytrigger an immune response against them resultingin the 
production of Auto Drug Antibodies (ADAs) which may 
neutralizetheir effects [19, 20]. This ultimately causes a secondary 
lack of efficacy and may alter pharmacologic properties of the 
bDMARDs. [4, 19, 20] This is not seen with JAKinibs [21]. 
Adverse effects of JA kinhibs 
 
Table 2: Showing side effects encountered with olumiant (Baricitinib) 4 mg once daily for 16 w (Data taken from 6 placebo-controlled 
studies) [22] 
Very common  (≥1/10) Common (≥1/100 to<1/10) Uncommon (≥1/1,000 to<1/100) 
URTI Herpes zoster, Herpes simplex, 
Gastroenteritis, Urinary tract infections 
Neutropenia 
Hypercholesterolemia Thrombocytosis Hypertriglyceridemia 
 Nausea Acne 
 ALT increased ≥3 x upper limit of normal AST increased ≥3 x upper limit of normal 
  Weight increased 
  Creatine phosphokinase increased ≥5 x upper limit of normal 
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Blocking signal transmission by the inhibition of JAK has potentially 
serious implications. Tofacitinib’s safety profile has been studied in 
multiple trials. At clinically approved doses, it appears generally well 
tolerated and has a similar safety profile to that of bDMARDs, apart from 
an increased risk of viral infections (herpes zoster). However, Tofacitinib 
has a relatively short half-life (3 h) compared to bDMARDs, thus in case 
of a severe infection, the drug can be withheld and the 
immunosuppressive effect rapidly eliminated [1, 23, 24]. More serious 
side effects such as the occurrence of malignancies are possible because 
Tofacitinib inhibits signalling by IL-2 and IL-15 which are important for 
the differentiation and activation of Natural Killer cells [12]. A serious 
adverse event reported with the use of baricitinib is the increased risk of 
thrombosis; deep vein thrombosis and pulmonary embolism as well as 
arterial thrombosis. Extra caution should be taken when prescribing 
baricitinib in patients with a raised risk of thrombosis [25]. 
Recommendations for RA 
According to the American College of Rheumatology (ACR) guideline 
and the recommendations of the European League against 
Rheumatism (EULAR), treatment for RA should be initiated with 
methotrexate (MTX). If disease control isn’t achieved with MTX 
monotherapy plus a short trial of glucocorticoids, the ACR guidelines 
recommend the use of either a combination of conventional 
synthetic Disease modifying anti rheumatic drugs (csDMARD), a 
biologic DMARD (bDMARD)+/-MTX, or Tofacitinib+/-MTX. The 
combination of tofacitinib+/-MTX may be considered as an 
alternative inbDMARD-refractory RA patients.[26]The EULAR 
suggest consideration of the addition of either tofacitinib or 
baricitinib to the treatment regimen of MTX inadequate responders 
or bDMARD inadequate responders in patients with RA [26]. 
For the treatment of PsA, Tofacitinib has been approved for use in 
the United States and the European Union, where it is indicated for 
use in combination with MTX in patients who have not had adequate 
response to therapy or those that have been intolerant to previous 
therapy with DMARDs [27]. 
Monitoring protocol 
In general, prior toinitiation of treatmentwith JAKinibs, patients should 
be screened for viral hepatitis and latent tuberculosis (TB). Anti-TB 
treatment should be considered in patients who have untreated latent 
TB. Patients should also have a baselinecomplete blood count 
performedprior to the initiation of treatment and (importantly Hb, 
absolute neutrophil, lymphocyte count, platelets), liver and kidney 
function test at baseline, plus a lipid profile. Also, measuring blood 
pressure and heart rate at baselineis recommended, and a periodic 
examination of skin in patients at increased risk of skincancer. Patients 
should be up to date with their immunisations and live vaccines should 
be avoided during treatment with JAKinibs [22-24]. 
CONCLUSION 
The emergence of JAK inhibitors promises the start of a revolution in 
the treatment of various chronic diseases. Their efficacy and safety 
profile hasbeen demonstrated in multiple trials and JAKinibs have 
been licensed for the treatment ofa number of diseases including RA 
and PsA. Moreover, the use of highly selective JAKinibs is currently 
being studied aiming to reduce side effects compared with 
traditional JAKinibs. An example of that would be the recently FDA 
approved upadacitinib [1, 6]. It remains to be seen whether the 
JAKinibs will replace the classical biologic agents in the treatment of 
autoimmune diseases, but they hold some clear advantages; oral 
administration, blockade of multiple cytokines simultaneously, 
reversibilityand the lack of immunogenicity [4, 8, 18-20]. 
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